Free Trial
→ Elon’s Chosen Ones (From Altimetry) (Ad) Free JNJ Stock Alerts

Johnson & Johnson (JNJ) Short Interest Ratio & Short Volume

Johnson & Johnson logo
$152.83 +1.68 (+1.11%)
As of 11:03 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Johnson & Johnson Short Interest Data

Johnson & Johnson (JNJ) has a short interest of 16.46 million shares, representing 0.69% of the float (the number of shares available for trading by the public). This marks a -6.32% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.2, indicating that it would take 2.2 days of the average trading volume of 9.28 million shares to cover all short positions.

Current Short Interest
16,460,000 shares
Previous Short Interest
17,570,000 shares
Change Vs. Previous Month
-6.32%
Dollar Volume Sold Short
$2.38 billion
Short Interest Ratio
2.2 Days to Cover
Last Record Date
January 15, 2025
Outstanding Shares
2,407,620,000 shares
Short Percent of Float
0.69%
Today's Trading Volume
989,176 shares
Average Trading Volume
9,276,673 shares
Today's Volume Vs. Average
11%
Short Selling Johnson & Johnson?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Johnson & Johnson and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

JNJ Short Interest Over Time

JNJ Days to Cover Over Time

JNJ Percentage of Float Shorted Over Time

Johnson & Johnson Short Interest History

Export to Excel
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/15/202516,460,000 shares $2.38 billion -6.3%0.7%2.2 $144.74
12/31/202416,460,000 shares $2.38 billion -6.3%0.7%2.2 $144.62
12/15/202417,570,000 shares $2.58 billion -5.2%0.7%2.4 $146.62
11/30/202418,540,000 shares $2.87 billion +6.1%0.8%2.8 $155.01
11/15/202417,480,000 shares $2.69 billion -3.5%0.7%2.7 $153.99
10/31/202418,110,000 shares $2.90 billion -3.0%0.8%2.9 $159.86
10/15/202418,660,000 shares $3.06 billion -5.5%0.8%2.9 $164.14
9/30/202419,740,000 shares $3.20 billion -14.3%0.8%3 $162.02
9/15/202423,030,000 shares $3.81 billion +9.0%1.0%3.5 $165.52
8/31/202421,130,000 shares $3.50 billion +6.7%0.9%3.1 $165.86
8/15/202419,810,000 shares $3.15 billion +5.1%0.8%2.7 $159.10
7/31/202418,850,000 shares $2.98 billion +4.8%0.8%2.6 $157.85
7/15/202417,990,000 shares $2.68 billion -15.0%0.8%2.4 $149.24
6/30/202421,170,000 shares $3.09 billion +8.2%0.9%2.8 $146.16
6/15/202419,560,000 shares $2.85 billion -1.9%0.8%2.6 $145.54
5/31/202419,930,000 shares $2.93 billion +14.3%0.8%2.6 $146.83
5/15/202417,430,000 shares $2.66 billion -1.4%0.7%2.3 $152.70
4/30/202417,670,000 shares $2.56 billion +6.7%0.7%2.3 $144.61
4/15/202416,560,000 shares $2.44 billion +3.9%0.7%2.2 $147.49
3/31/202415,940,000 shares $2.52 billion +0.6%0.7%2.3 $158.19
3/15/202415,840,000 shares $2.51 billion +6.7%0.7%2.3 $158.18
2/29/202414,850,000 shares $2.40 billion +35.5%0.6%2.1 $161.37
2/15/202410,960,000 shares $1.73 billion -10.9%0.5%1.5 $157.92
1/31/202412,300,000 shares $1.95 billion -18.1%0.5%1.8 $158.90
1/15/202415,010,000 shares $2.44 billion +20.4%0.6%2.2 $162.39
12/31/202312,470,000 shares $1.95 billion -19.0%0.5%1.8 $156.74
12/15/202315,400,000 shares $2.39 billion +2.7%0.6%2.2 $155.04
11/30/202315,000,000 shares $2.32 billion +13.7%0.6%2.2 $154.65
11/15/202313,190,000 shares $1.96 billion -9.2%0.6%1.8 $148.81
10/31/202314,530,000 shares $2.16 billion -7.3%0.6%0.7 $148.34
10/15/202315,680,000 shares $2.46 billion -11.6%0.7%0.7 $156.85
9/30/202317,730,000 shares $2.76 billion -20.4%0.7%0.8 $155.75
9/15/202322,260,000 shares $3.59 billion -32.3%0.9%1 $161.43
8/31/202332,860,000 shares $5.31 billion -61.6%1.4%1.5 $161.68
8/15/202385,500,000 shares $14.78 billion +232.3%3.3%4 $172.92
7/31/202325,730,000 shares $4.31 billion +113.0%1.0%2.7 $167.53
7/15/202312,080,000 shares $1.93 billion -7.0%0.5%1.7 $159.87
6/30/202312,990,000 shares $2.15 billion -9.5%0.5%2 $165.52
6/15/202314,350,000 shares $2.35 billion -2.8%0.6%2.1 $163.75
5/31/202314,770,000 shares $2.29 billion +9.6%0.6%2.1 $155.06
Please take this warning seriously... (Ad)

I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as March 13th… Meaning you don’t have much time to prepare.

Click here like your financial health depends on it.
5/15/202313,480,000 shares $2.15 billion +5.8%0.5%1.8 $159.55
4/30/202312,740,000 shares $2.09 billion -9.5%0.5%1.6 $163.70
4/15/202314,070,000 shares $2.33 billion +11.1%0.5%1.6 $165.84
3/31/202312,670,000 shares $1.96 billion +0.6%0.5%1.5 $155.00
3/15/202312,590,000 shares $1.94 billion +7.4%0.5%1.6 $154.35
2/28/202311,720,000 shares $1.80 billion +33.6%0.5%1.5 $153.26
2/15/20238,770,000 shares $1.40 billion -4.4%0.3%1.2 $159.37
1/31/20239,170,000 shares $1.50 billion +8.3%0.4%1.3 $163.42
1/15/20238,470,000 shares $1.47 billion -15.1%0.3%1.3 $173.43
12/30/20229,980,000 shares $1.76 billion -18.8%0.4%1.5 $176.65
12/15/202212,290,000 shares $2.18 billion -4.5%0.5%1.8 $177.49
11/30/202212,870,000 shares $2.29 billion +1.7%0.5%1.8 $178.00
11/15/202212,660,000 shares $2.18 billion +2.5%0.5%1.8 $172.39
10/31/202212,350,000 shares $2.15 billion +10.0%0.5%1.7 $173.97
10/15/202211,230,000 shares $1.85 billion -13.2%0.4%1.6 $164.46
9/30/202212,940,000 shares $2.11 billion -8.5%0.5%1.9 $163.36
9/15/202214,140,000 shares $2.33 billion +16.0%0.5%2 $165.08
8/31/202212,190,000 shares $1.97 billion +12.1%0.5%1.8 $161.34
8/15/202210,870,000 shares $1.81 billion -8.5%0.4%1.6 $166.09
7/31/202211,880,000 shares $2.07 billion -12.7%0.5%1.8 $174.52
7/15/202213,610,000 shares $2.43 billion -4.4%N/A1.9 $178.23
6/30/202214,240,000 shares $2.53 billion -7.5%N/A1.9 $177.51
6/15/202215,390,000 shares $2.62 billion -11.8%N/A2.1 $169.99
5/31/202217,440,000 shares $3.13 billion +14.6%N/A2.3 $179.53
5/15/202215,220,000 shares $2.69 billion -12.9%N/A1.9 $176.85
4/30/202217,480,000 shares $3.15 billion +17.9%0.7%2.2 $180.46
4/15/202214,830,000 shares $2.67 billion +3.3%0.6%1.8 $179.90
3/31/202214,350,000 shares $2.54 billion -7.8%0.6%1.8 $177.23
3/15/202215,560,000 shares $2.74 billion +3.6%0.6%2 $176.14
2/28/202215,020,000 shares $2.47 billion -2.2%0.6%1.9 $164.57
2/15/202215,360,000 shares $2.57 billion +0.6%N/A1.9 $167.31
1/31/202215,270,000 shares $2.63 billion +6.0%N/A2 $172.29
1/15/202214,410,000 shares $2.42 billion -6.3%N/A1.9 $167.84
12/31/202115,370,000 shares $2.63 billion -9.9%N/A2.1 $171.07
12/15/202117,060,000 shares $2.92 billion +2.5%N/A2.3 $171.14
11/30/202116,640,000 shares $2.59 billion +10.6%N/A2.3 $155.93
11/15/202115,040,000 shares $2.46 billion -8.9%N/A2.3 $163.52
10/29/202116,510,000 shares $2.69 billion +1.9%N/A2.7 $162.88
10/15/202116,200,000 shares $2.61 billion -0.9%N/A2.7 $161.30
9/30/202116,340,000 shares $2.64 billion -5.4%N/A2.8 $161.50
9/15/202117,270,000 shares $2.86 billion +5.4%N/A2.9 $165.42
8/31/202116,390,000 shares $2.84 billion -1.9%N/A2.8 $173.13
8/13/202116,700,000 shares $2.94 billion -3.0%N/A2.8 $176.25
7/30/202117,220,000 shares $2.97 billion +9.3%N/A2.7 $172.20
7/15/202115,760,000 shares $2.65 billion +8.2%N/A2.4 $168.37
6/30/202114,560,000 shares $2.40 billion -4.0%N/A2.1 $164.74
6/15/202115,160,000 shares $2.49 billion +6.9%N/A2.1 $164.49
5/28/202114,180,000 shares $2.40 billion -8.2%N/A2 $169.25
5/14/202115,440,000 shares $2.62 billion +2.4%0.6%2 $169.96
4/30/202115,080,000 shares $2.48 billion +0.4%0.6%2 $164.20
Hot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapy (Ad)

A revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment. We live in a world where viruses are getting stronger and deadlier. What if there was a way to fight these viruses the way antibiotics fight bacteria? One small-cap biotech company has a treatment that was found to have possibly completely cured the lethal RSV infection in mice! This was based on indefinite survival of the animals with no lung pathology.

This small-cap biotech firm is revolutionizing antiviral therapy while building shareholder value. L
4/15/202115,020,000 shares $2.40 billion -7.9%0.6%1.8 $159.92
3/31/202116,300,000 shares $2.69 billion -4.3%0.6%2 $165.01
3/15/202117,040,000 shares $2.72 billion +12.0%0.7%2.1 $159.60
2/26/202115,220,000 shares $2.48 billion -0.3%0.6%1.9 $162.76
2/12/202115,260,000 shares $2.53 billion -2.1%0.6%1.9 $166.06
1/29/202115,590,000 shares $2.64 billion +15.8%0.6%1.9 $169.16
1/15/202113,460,000 shares $2.16 billion No Change0.5%1.7 $160.65
12/31/202013,460,000 shares $2.10 billion +3.5%0.5%1.8 $156.05
12/15/202013,010,000 shares $1.94 billion -6.9%0.5%1.8 $149.07
11/30/202013,970,000 shares $2.01 billion -4.3%0.5%2 $144.00
11/15/202014,590,000 shares $2.19 billion +14.3%0.6%2.2 $149.90
10/30/202012,770,000 shares $1.75 billion +13.9%0.5%2 $137.19
10/15/202011,210,000 shares $1.66 billion -2.1%0.4%1.9 $148.10
9/30/202011,450,000 shares $1.70 billion +11.3%0.4%1.9 $148.88
9/15/202010,290,000 shares $1.53 billion -2.6%0.4%1.7 $148.89
8/31/202010,560,000 shares $1.62 billion +12.0%0.4%1.6 $153.41
8/14/20209,430,000 shares $1.40 billion -24.0%0.4%1.4 $148.24
7/31/202012,400,000 shares $1.81 billion -0.9%0.5%1.8 $145.76
7/15/202012,510,000 shares $1.85 billion -2.1%0.5%1.7 $148.26
6/30/202012,780,000 shares $1.80 billion -7.1%0.5%1.6 $140.63
6/15/202013,760,000 shares $1.94 billion +5.8%0.5%1.5 $141.25
5/29/202013,010,000 shares $1.94 billion -20.1%0.5%1.2 $148.75
5/15/202016,280,000 shares $2.45 billion -3.3%0.6%1.4 $150.44
4/30/202016,830,000 shares $2.53 billion -11.8%0.6%1.4 $150.04
4/15/202019,070,000 shares $2.82 billion +13.6%0.7%1.7 $147.66
3/31/202016,790,000 shares $2.60 billion -17.4%0.6%1.5 $154.86
3/13/202020,336,100 shares $2.87 billion +22.3%0.8%2.7 $141.23
2/28/202016,630,000 shares $1.85 billion -8.4%0.6%2.2 $111.14
2/14/202018,160,000 shares $2.57 billion -13.0%0.7%2.7 $141.64
1/31/202020,870,000 shares $3.00 billion +2.2%0.8%3.3 $143.68

JNJ Short Interest - Frequently Asked Questions

What is Johnson & Johnson's current short interest?

Short interest is the volume of Johnson & Johnson shares that have been sold short but have not yet been covered or closed out. As of January 15th, traders have sold 16,460,000 shares of JNJ short. 0.69% of Johnson & Johnson's shares are currently sold short. Learn More on Johnson & Johnson's current short interest.

What is a good short interest ratio for Johnson & Johnson?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. JNJ shares currently have a short interest ratio of 2.0. Learn More on Johnson & Johnson's short interest ratio.

Which institutional investors are shorting Johnson & Johnson?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Johnson & Johnson: Genus Capital Management Inc., XY Capital Ltd, IMC Chicago LLC, Baader Bank Aktiengesellschaft, XR Securities LLC, Wealth Enhancement Advisory Services LLC, JPMorgan Chase & Co., Barclays PLC, Jane Street Group LLC, Wolverine Trading LLC, Readystate Asset Management LP, Point72 DIFC Ltd, Point72 Asset Management L.P., Parallax Volatility Advisers L.P., Maven Securities LTD, Centiva Capital LP, Berkley W R Corp, Garda Capital Partners LP, Verition Fund Management LLC, Capstone Investment Advisors LLC, Walleye Trading LLC, Walleye Capital LLC, PEAK6 Investments LLC, BNP Paribas Financial Markets, Bank of Montreal Can, Citigroup Inc., One River Asset Management LLC, LMR Partners LLP, Marathon Trading Investment Management LLC, Gladius Capital Management LP, Wolverine Asset Management LLC, XY Capital Ltd, and SpiderRock Advisors LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Johnson & Johnson?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.69% of Johnson & Johnson's floating shares are currently sold short.

Is Johnson & Johnson's short interest increasing or decreasing?

Johnson & Johnson saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 16,460,000 shares, a decrease of 6.3% from the previous total of 17,570,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Johnson & Johnson's short interest compare to its competitors?

0.69% of Johnson & Johnson's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Johnson & Johnson: Eli Lilly and Company (0.72%), AbbVie Inc. (0.96%), Merck & Co., Inc. (1.22%), Pfizer Inc. (1.34%), Bristol-Myers Squibb (1.23%), Zoetis Inc. (1.55%), Royalty Pharma plc (4.35%), Jazz Pharmaceuticals plc (6.65%), Corcept Therapeutics Incorporated (17.68%), Perrigo Company plc (3.30%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($6.03 billion), Charter Communications, Inc. ($3.83 billion), Reddit, Inc. ($3.11 billion), The Kroger Co. ($2.85 billion), International Paper ($2.73 billion), Rivian Automotive, Inc. ($2.02 billion), SoFi Technologies, Inc. ($2.00 billion), Onsemi ($1.59 billion), Live Nation Entertainment, Inc. ($1.58 billion), and First Solar, Inc. ($1.53 billion). View all of the most shorted stocks.

What does it mean to sell short Johnson & Johnson stock?

Short selling JNJ is an investing strategy that aims to generate trading profit from Johnson & Johnson as its price is falling. JNJ shares are trading up $1.68 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Johnson & Johnson?

A short squeeze for Johnson & Johnson occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JNJ, which in turn drives the price of the stock up even further.

How often is Johnson & Johnson's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JNJ, twice per month. The most recent reporting period available is January, 15 2025.



Related Companies
Short Interest Tools

This page (NYSE:JNJ) was last updated on 1/30/2025 by MarketBeat.com Staff
From Our Partners
#1 Crypto of 2025
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...
True Market Insiders | Sponsored
We recommended Palantir in 2021, now we’re recommending this...
I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...
Behind the Markets | Sponsored
This Crypto Is Set to Explode in January
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...
Crypto 101 Media | Sponsored
Is Big Tech dead?
China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...
Brownstone Research | Sponsored
Alert: DOGE goes live
"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...
Altimetry | Sponsored
Donald Trump is about to free crypto from its chains …
On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...
Weiss Ratings | Sponsored
Please take this warning seriously...
I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...
Timothy Sykes | Sponsored
Hot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapy
A revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....
Smallcaps Daily | Sponsored